Program
VC005
A development code. Also written as “VC005 tablets”, “VC005 Tablets” and “VC005 and verapamil”.
Its studies are mostly in Dermatitis, Atopic · Alopecia Areata · Vitiligo · Spondylitis, Ankylosing · Inflammatory Bowel Diseases, led by Jiangsu vcare pharmaceutical technology.
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu vcare pharmaceutical technology | 219 open or running | phase 3since Dec 5, 2024 | Oct 25, 2021 | Nov 30, 2026phase 1 · NCT07796191 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
Before these, 4 studies since Oct 25, 2021.
- Aug 10, 2023Phase 2 study in Moderate to Severe Atopic DermatitisNCT05997927 · 149 enrolled · China
- Aug 18, 2023Phase 1 study in Dermatitis, AtopicNCT06009094 · 80 enrolled · China
- Dec 5, 2024Phase 3 study in Moderate to Severe Atopic DermatitisNCT06723080 · 480 planned · China
- Mar 18, 2025Phase 2 study in Dermatitis, AtopicNCT06891040 · 118 enrolled · China
- May 6, 2025Phase 1 study in Dermatitis, AtopicNCT06974292 · 6 enrolled · China
- Sep 8, 2025Phase 3 study in Active Ankylosing SpondylitisNCT07172360 · 420 planned · China
- Sep 8, 2025Phase 2 study in Non-segmental VitiligoNCT07172347 · 120 planned · China
- Dec 29, 2025Phase 1 study in Dermatitis, AtopicNCT07329101 · 11 enrolled · China
- Apr 10, 20263 phase 1 studiesNCT07533851, NCT07551570, NCT07551557
- May 12, 2026Phase 3 study in Dermatitis, AtopicNCT07592585 · 360 planned · China
- May 14, 2026Phase 2 study in Dermatitis, AtopicNCT07598383 · 120 planned · China
- Aug 3, 2026Phase 2 study in Alopecia AreataNCT07749716 · 120 planned · China
- Aug 9, 20262 phase 1 studiesNCT07762443, NCT07796191
- Sep 15, 2026Phase 2 study in Non-Segmental VitiligoNCT07828639 · 10 planned · China
Ahead
- Nov 30, 2026Primary completion: phase 1 study in Healthy Adult ParticipantsNCT07796191
- Feb 22, 2027Primary completion: phase 2 study in Dermatitis, AtopicNCT07598383
- May 30, 2027Primary completion: phase 2 study in Non-Segmental VitiligoNCT07828639
- Aug 30, 2027Primary completion: phase 3 study in Active Ankylosing SpondylitisNCT07172360
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 21 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07828639Non-Segmental Vitiligo · China | 2 | Not yet recruiting | May 30, 2027 | 10 |
| NCT07796191Healthy Adult Participants · China | 1 | Not yet recruiting | Nov 30, 2026 | 84 |
| NCT07762443Alopecia Areata · China | 1 | Recruiting | Dec 30, 2027 | 24 |
| NCT07749716Alopecia Areata · China | 2 | Recruiting | Dec 30, 2028 | 120 |
| NCT07598383Dermatitis, Atopic · China | 2 | Recruiting | Feb 22, 2027 | 120 |
| NCT07592585Dermatitis, Atopic · China | 3 | Recruiting | May 30, 2028 | 360 |
| NCT07551570Renal Insufficiency · China | 1 | Completed | Aug 2, 2026 | 32 |
| NCT07551557Hepatic Impairment and Healthy Female · China | 1 | Completed | Aug 2, 2026 | 24 |
| NCT07533851Dermatitis, Atopic · China | 1 | Completed | Apr 30, 2026 | 31 |
| NCT07329101Dermatitis, Atopic · China | 1 | Completed | Feb 6, 2026 | 11 |
| NCT07172360Active Ankylosing Spondylitis · China | 3 | Recruiting | Aug 30, 2027 | 420 |
| NCT07172347Non-segmental Vitiligo · China | 2 | Recruiting | Aug 30, 2027 | 120 |
| NCT06974292Dermatitis, Atopic · China | 1 | Completed | Jun 3, 2025 | 6 |
| NCT06891040Dermatitis, Atopic · China | 2 | Completed | Oct 31, 2025 | 118 |
| NCT06723080Moderate to Severe Atopic Dermatitis · China | 3 | Recruiting | Aug 30, 2027 | 480 |
| NCT06009094Dermatitis, Atopic · China | 1 | Completed | May 23, 2024 | 80 |
| NCT05997927Moderate to Severe Atopic Dermatitis · China | 2 | Completed | Jul 9, 2024 | 149 |
| NCT05874622Arthritis, Rheumatoid · China | 1 | Completed | Oct 18, 2023 | 30 |
| NCT05814939Active Ankylosing Spondylitis · China | 2 | Completed | May 11, 2024 | 180 |
| NCT05354752Inflammatory Bowel Diseases · China | 1 | Completed | Nov 2, 2022 | 60 |
| NCT05138770Inflammatory Bowel Diseases · China | 1 | Completed | Aug 26, 2022 | 78 |
How it is read
Names in the registry
- “VC005 tablets”, 9 entries
- “VC005 Tablets”, 5 entries
- “VC005”, 3 entries
- “VC005 and verapamil”, 1 entry
- “VC005 and probenecid”, 1 entry
Codes read as this program: VC005.
Conditions, from the studies’ own filings
- Dermatitis, Atopic, 9 studies
- Alopecia Areata, 2 studies
- Vitiligo, 2 studies
- Spondylitis, Ankylosing, 2 studies
- Inflammatory Bowel Diseases, 2 studies
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.